AMP-AD Data Coordination Center

AMP-AD数据协调中心

• 批准号: 10475219
• 负责人: ANNA K GREENWOOD
• 金额: $ 241.3万
• 依托单位: SAGE BIONETWORKS
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-30 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10475219
• 关键词: Address; Affect; Alzheimer' s Disease; Alzheimer' s disease model; Alzheimer' s disease risk; American; Benchmarking; Bioinformatics; Biological; Biological Models; Biological Process; Biology; Communities; Community Outreach; Complex; Computer Models; Data; Data Coordinating Center; Disease; Ecosystem; Environment; Environmental Risk Factor; Evaluation; Evaluation Research; Experimental Models; Genetic; Goals; Grant; Human; Individual; Informatics; Investments; Knowledge Portal; Lead; Medicine; Meta-Analysis; Methods; Molecular; Neurodegenerative Disorders; Outcome; Outcomes Research; Performance; Persons; Privatization; Process; Reproducibility; Research; Research Personnel; Research Project Grants; Resource Sharing; Resources; Services; Sister; Source; Standardization; System; Systems Biology; Therapeutic; Training; Validation; Work; biomarker discovery; biomarker identification; causal variant; cloud based; data tools; design; differential expression; digital; drug development; drug discovery; human model; improved; insight; multiple data sources; open data; pre-clinical; prevent; programs; repository; resilience; risk variant; therapeutic target; tool; transcriptome sequencing; transcriptomics; working group

Project Summary/Abstract Alzheimer’s Disease (AD) is a debilitating neurodegenerative disease affecting more than 5 million Americans. Despite significant investment in drug discovery and development, no therapeutic options yet exist that can prevent, slow, or cure AD. The Accelerating Medicines Partnership in Alzheimer’s Disease Target Discovery and Preclinical Validation project (AMP-AD) was designed to help address this problem by identifying candidate targets through evaluation of AD-induced changes in human molecular state on a systems level. The program uses an open science paradigm to support early, iterative integration of resources and evaluation of findings across multiple independent teams. This approach was designed to improve observations through integration of multiple data sources, to increase confidence in outcomes through transparency, reproducibility, and benchmarking of methods and to accelerate evaluation of nominated AD targets by aggregating evidence and expertise across the field. Cross-consortium activities are supported by the Data Coordination Center (DCC) led by Sage Bionetworks. Functions include resource sharing, performance of cross-team analytical projects, and coordinated evaluation across the program of research outcomes. The overarching goal of AMP- AD Data Coordinating Center is to advance the AMP-AD research program through open science practices for coordinated and integrated evaluation of AD targets. As the AMP-AD community expands in terms of people, data, and research projects, several extensions to the existing DCC services are necessary to fully support the program. These include: (a) improved mechanisms to identify resources across the expanding spectrum of projects, (b) support for biologists without informatics expertise to interpret and use AD systems biology resources, (c) mechanisms to integrate external expertise and/or resources where they are needed to advance program goals, and (d) targeted analyses that serve to bridge analytical gaps across individual projects. By combining existing services with these advancements, the DCC will work to: 1. Distribute AMP-AD systems biology assets through the AMP-AD Knowledge Portal. 2. Integrate research efforts across AMP-AD projects through cross-team analyses. 3. Expand the broader impact of AMP-AD through community outreach. The proposed work is designed to maximize the vast resources and biological insights within AMP-AD and to accelerate characterization and validation of AMP-AD targets through the open dissemination and evaluation of a set of high-confidence therapeutic targets.

项目概要/摘要 阿尔茨海默病 (AD) 是一种使人衰弱的神经退行性疾病，影响着超过 500 万美国人。 尽管在药物发现和开发方面投入了大量资金，但尚不存在可以 预防、减缓或治愈阿尔茨海默病的药物合作加速目标发现。 临床前验证项目（AMP-AD）旨在通过识别来帮助解决这个问题 通过在系统水平上评估 AD 引起的人类分子状态变化来候选目标。 该计划使用开放科学范式来支持早期、迭代的资源整合和评估 这种方法旨在通过多个独立团队的发现来改善观察结果。 整合多个数据源，通过透明度、可重复性来增强对结果的信心， 方法和基准测试，并通过汇总证据加速对提名的 AD 目标的评估 跨联盟活动得到数据协调中心的支持。 (DCC) 由 Sage Bionetworks 领导，职能包括资源共享、跨团队分析性能。 AMP- 的总体目标。 AD 数据协调中心将通过开放科学实践推进 AMP-AD 研究计划 AD 目标的协调和综合评估 随着 AMP-AD 社区在人员方面的扩大， 数据和研究项目，现有 DCC 服务的一些扩展是必要的，以充分支持 其中包括： (a) 改进机制，以在不断扩大的范围内识别资源。 项目，(b) 支持没有信息学专业知识的生物学家解释和使用 AD 系统生物学 资源，(c) 在需要时整合外部专业知识和/或资源的机制 计划目标，以及 (d) 有针对性的分析，以弥补各个项目之间的分析差距。 将现有服务与这些进步相结合，DCC 将致力于： 1. 分发 AMP-AD 系统 通过 AMP-AD 知识门户获取生物资产 2. 整合 AMP-AD 项目的研究工作。 3. 通过社区外展扩大 AMP-AD 的影响。 拟议的工作旨在最大限度地利用 AMP-AD 中的大量资源和生物学见解，并 通过公开传播和评估加速 AMP-AD 目标的表征和验证 一组高可信度的治疗目标。